ResoTher, Pharma

ResoTher Pharma receives a €2.5 million grant from European Innovation Council to support a Phase 2a clinical study of their Lead Candidate RTP-026 for Myocardial Infarction

Veröffentlicht: 07.08.2025 um 18:07 Uhr, prnewswire.co.uk

ResoTher Pharma ApS Denmark United States of America England United Kingdom

or follow us on LinkedIn.

Logo - https://mma.prnewswire.com/media/2267692/ResoTher_Pharma_ApS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/resother-pharma-receives-a-2-5-million-grant-from-european-innovation-council-eic-to-support-a-phase-2a-clinical-study-of-their-lead-candidate-rtp-026-for-myocardial-infarction-301979077.html

en | boerse | 67943104 |